MedTrace Logo

ArtiAid® Plus for Knee Osteoarthritis: A Post-market Study

NCT05881317 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-05-31

No results posted yet for this study

Summary

The goal of this open-label, post-market clinical follow-up study is to demonstrate the safety and performance of ArtiAid® Plus Intra-articular Injection in patients with knee osteoarthritis(OA). The main questions it aims to answer are:

* the safety profile of ArtiAid® Plus;
* the clinical performance of ArtiAid® Plus, such as pain relief and satisfaction of treatment.

Participants will receive weekly injections of ArtiAid® Plus for 3 weeks and be follow-up for 26 weeks.

Conditions

  • Hyaluronic Acid

Interventions

DEVICE

ArtiAid® Plus Intra-articular Injection

Inject ArtiAid® Plus in the affected joint at weekly interval for 3 weeks

Sponsors & Collaborators

  • Maxigen Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • Cheng Fong Chen · Taipei Veterans General Hospital, Taiwan

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-02
Primary Completion
2022-06-06
Completion
2022-11-21

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05881317 on ClinicalTrials.gov